Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Duloxetine in the prevention of relapse of major depressive disorder: Double-blind placebo-controlled study

  • David G. Perahia, Inmaculada Gilaberte, Fujun Wang, Curtis G. Wiltse, Stacy A. Huckins, Jeffrey W. Clemens, Stuart A. Montgomery, Angel L. Montejo, Michael J. Detke
  • Journal:
    The British Journal of Psychiatry / Volume 188 / Issue 4 / April 2006
    Published online by Cambridge University Press:
    02 January 2018, pp. 346-353
    Print publication:
    April 2006
    • Article
      • You have access
    • PDF
    • HTML
    • Export citation
  • Background

    Relapse rates may be as high as 50% in people with major depressive disorder (MDD) previously treated to remission.

    Aims

    Duloxetine, an inhibitor of serotonin and noradrenaline reuptake that is licensed in Europe, the USA and elsewhere for the treatment of depressive episodes, was evaluated with regard to its efficacy, safety and tolerability in the prevention of relapse of MDD.

    Method

    Adult out-patients with MDD received duloxetine (60 mg daily) for 12 weeks (n=533). Patients who responded to the drug were then randomised to duloxetine (60 mgdaily) (n=136) or placebo (n=142) for 26 weeks. The primary measure of efficacy was time to relapse.

    Results

    Patients who received duloxetine (60 mg daily) experienced significantly longer times to relapse of MDD, and better efficacy global well-being, and quality-of-life outcomes compared with patients who received placebo. It should be noted that adverse events which occur in discontinuation may mimic some signs of depressive relapse, and were not specifically elicited in this study.

    Conclusions

    Duloxetine (60 mg daily) is effective in the prevention of relapse of MDD during continuation treatment.